Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational Study of Blinatumomab Safety and Effectiveness, Utilization, and Treatment Practices

NCT03117621 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT03117621
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03117621 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational Study of Blinatumomab Safety and Effectiveness, Utilization, and Treatment Practices
Lead sponsor
Amgen
Phase
Observational
Overall status
Completed
Start date
March 22, 2017
Completion date
March 20, 2024
Enrollment
279 (actual)
Sites
80

Conditions

As the registry lists them; a condition with its own page is linked.

blincyto use in routine clinical practice